Lu Ming, Yao Wan-zhen, Chen Ya-hong, Ding Yan-ling, Chang Chun, Tang Chao-shu
Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100083, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Apr 18;38(2):155-8.
To investigate the roles of urotensin II (U-II) in chronic obstructive pulmonary disease (COPD).
Plasma and induced sputum were obtained from thirty four patients with stable COPD and ten healthy volunteers. The levels of U-II in plasma and induced sputum were measured by RIA kit. Lung function was performed routinely. Induced sputum cells were counted with hemacytometer and differentiated with Wright-Giemsa stain.
The levels of U-II in induced sputum were 82 and 65 folds higher than those of plasma U-II in COPD patients and healthy controls (P<0.01). The levels of U-II in plasma were unrelated to those of induced sputum (r = 0.168, P>0.05). No difference was noted between COPD and healthy controls in the plasma U-II levels [1.46(1.15, 1.73) vs 1.61(1.31, 2.17) microg/L, medians with interquartile ranges, P>0.05]. Sputum U-II levels from COPD patients were 15% higher than those of healthy controls [119.87(105.03, 132.60) vs 104.44 (56.33, 122.24) microg/L, medians with interquartile ranges, P<0.05]. Induced sputum U-II levels of COPD patients had a trend of increase as lung function deteriorated and smoking index increases. Raised sputum total cell and neutrophil counts correlated strongly with the levels of U-II in induced sputum (r = 0.454, r = 0.431, both P<0.01). The levels of U-II in induced sputum correlated negatively with FEV(1)% predicted and p(O(2)) (r = -0.417, r = -0.518, both P<0.05).
U-II may act locally, or, via paracrine or autocrine way, play a role in the mechanism of the airway inflammation and airway remodeling in COPD.
探讨尾加压素II（U-II）在慢性阻塞性肺疾病（COPD）中的作用。
收集34例稳定期COPD患者及10名健康志愿者的血浆和诱导痰。采用放射免疫分析试剂盒检测血浆和诱导痰中U-II水平。常规进行肺功能检查。用血细胞计数仪对诱导痰细胞进行计数，并用瑞氏-吉姆萨染色进行鉴别。
COPD患者和健康对照者诱导痰中U-II水平分别比血浆U-II水平高82倍和65倍（P<0.01）。血浆U-II水平与诱导痰U-II水平无关（r = 0.168，P>0.05）。COPD患者与健康对照者血浆U-II水平无差异[1.46(1.15, 1.73) 对1.61(1.31, 2.17) μg/L，中位数及四分位数间距，P>0.05]。COPD患者痰U-II水平比健康对照者高15%[119.87(105.03, 132.60) 对104.44 (56.33, 122.24) μg/L，中位数及四分位数间距，P<0.05]。COPD患者诱导痰U-II水平随肺功能恶化和吸烟指数增加呈升高趋势。诱导痰中总细胞数和中性粒细胞数升高与诱导痰中U-II水平密切相关（r = 0.454，r = 0.431，均P<0.01）。诱导痰中U-II水平与预测的第一秒用力呼气容积（FEV₁）百分比及氧分压（p(O₂)）呈负相关（r = -0.417，r = -0.518，均P<0.05）。
U-II可能通过局部作用，或经旁分泌或自分泌方式，在COPD气道炎症和气道重塑机制中发挥作用。
